Clinical trial NCT04839328: A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Official title: A Phase Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled To Assess Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Psoriasis
Lead sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2021-04-09
Enrollment: 306
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. After single asending dose and mutiple asending dose in health subjects. phase 2 results suggest Hemay005 60 mg BID has a higher curative effect trend，and adverse reactions were mild, so we choose 60 mg BID as Hemay005 phase 3 dosage And the patients with moderate to severe plaque psoriasis will be randomized into 2 cohorts(60mg BID and placebo) approximately 306 subjects will be enrolled (204 in 60mg BID and 102 in placebo). This study includes an 16-week treatment Period, then a 36-week Treatment Period without placebo.

Detailed description: Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. After single asending dose and mutiple asending dose in health subjects. phase 2 results suggest Hemay005 60 mg BID has a higher curative effect trend，and adverse reactions were mild, so we choose 60 mg BID as Hemay005 phase 3 dosage And the patients with moderate to severe plaque psoriasis will be randomized into 2 cohorts(60mg BID and placebo) approximately 306 subjects will be enrolled (204 in 60mg BID and 102 in placebo). This study includes an 16-week treatment Period, then a 36-week Treatment Period without placebo.

Primary Objectives:

To evaluate the effectiveness of Hemay005 tablets 60 mg twice daily (BID) compared with placebo in patients with moderate to severe chronic plaque psoriasis.

Secondary objective：

1. Evaluate other efficacy characteristics of Hemay005 tablets 60 mg BID compared with placebo in patients with moderate to severe chronic plaque psoriasis.
2. Evaluate the safety of Hemay005 tablets 60 mg BID in patients with moderate to severe chronic plaque psoriasis.
3. To evaluate the population pharmacokinetics (PPK) characteristics of Hemay005 tablets 60 mg BID in patients with moderate to severe chronic plaque psoriasis.

Eligibility criteria: Inclusion Criteria:

1. At the time of signing the informed consent, the age was more than or equal to 18 years old, regardless of gender；
2. Stable plaque psoriasis with a history of more than 6 months (from the time of randomization)；
3. Screening and baseline PSAI ≥12, sPGA≥3（Moderate to Severe）,affected body surface area BSA≥10%；
4. All subjects must agree and commit to the use of a reliable contraceptive regimen. Women of childbearing potential must undergo monthly pregnancy testing during the study and agree to use two of the following methods of contraception throughout the study and for 90 days after the last dose of study drug. Reliable contraceptive regimen: vasectomy, abstinence, the use of condoms, intrauterine contraceptives (IUD), (Oral administration, patch, ring, injection, implantation) Barrier methods (diaphragm with spermicide, condom with spermicide)；
5. The subjects voluntarily participated in the study and signed the informed consent .

Exclusion Criteria:

1. Forms of psoriasis other than chronic plaque-type; (i.e., erythrodermic and guttate psoriasis, palmar, plantar or nail disease) at screening;
2. Investigator diagnosed as drug-induced psoriasis (including but not limited to new onset or aggravation of psoriasis caused by beta blockers, calcium channel inhibitors or lithium preparations);
3. Skin diseases, chronic diarrhea, serious digestive system diseases (such as active gastric ulcer, gastrointestinal bleeding, etc.), or other autoimmune inflammatory diseases that may interfere with clinical evaluation, according to the investigator;
4. The screening period was accompanied with active infection (such as bacterial infection, viral infection, fungal infection, etc., which required oral or intravenous treatment), and the investigator assessed that participation in this study may increase the risk of subjects;
5. Subjects with a history of tuberculosis or active tuberculosis (there were signs or symptoms of active tuberculosis judged by the researcher at the time of screening);
6. Use of prohibited treatments of this study;
7. History of congenital or acquired immunodeficiency;
8. Subjects couldn't limit their uv exposure during the study period ;
9. History of apremilast or Hemay005 tablets;
10. Subjects with conditions that may affect oral drug absorption, such as subtotal gastrectomy, clinically significant diabetic gastroenteropathy, or certain types of weight-loss surgery, such as gastric bypass surgery, do not include surgery that simply separates the stomach into separate Chambers, such as gastric banding surgery;
11. Subjects with tumor or history of malignancy (solid organ tumor or hematological tumor including myelodysplastic syndrome) in the past 5 years;
12. History of alcohol or drug abuse or dependence in the past year;
13. Subjects with a history of mental illness, suicidal behavior (including positive attempt, interrupted attempt or attempted suicide) or suicidal thoughts in the past 6 months were not suitable for clinical trials after the evaluation of the investigator; subjects with severe anxiety or depression during the screening period were assessed as severe anxiety or depression;
14. There are clinically serious, progressive or uncontrollable diseases in the screening period, including but not limited to respiratory system, cardiovascular system, endocrine system, blood system, musculoskeletal system and nervous system. According to the assessment of investigator, participating in this study may increase the risk of subjects or interfere with data interpretation;
15. In the screening period, human immunodeficiency virus (HIV) serological positive (i.e., HIV antibody positive);Evidence of hepatitis B virus infection: hepatitis B surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive and HBV-DNA above the upper limit of the normal range, or hepatitis B E antibody (HBeAb) positive and HBV-DNA above the upper limit of the normal range;Evidence of hepatitis C virus (HCV) infection: HCV antibody positive;
16. During the screening period, there were any of the following laboratory abnormalities:

    1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 times the upper limit of normal value, or total bilirubin \> 1.5 times the upper limit of normal value;
    2. Serum creatinine \> 1.2 times the upper limit of normal value;
    3. The hemoglobin of male patients was less than 8.5 g / dl (85.0 g / L), and that of female patients was less than 8.0 g / dl (80.0 g / L);
    4. WBC count \< 3.0 × 109 / L or ≥ 14 × 109 / L;
    5. Platelet count \< 100 × 109 / L
17. Female who were pregnant during lactation or pregnancy, or during the planned study period, or subjects who had sperm / egg donation plans during the study period;
18. Know allergic to active ingredient or excipient of the investigational product;
19. Participated in any other interventional clinical trial within 4 weeks or 5 pharmacokinetic / pharmacodynamic half lives before randomization (whichever is longer);
20. The investigator considered that there are any other conditions that are not suitable for participating in the study.

Primary outcomes:
measure: Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75).
timeFrame: week 16
Secondary outcomes:
measure: Proportion of subjects achieving an overall sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline.
timeFrame: week 16
measure: Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75).
timeFrame: 1 year
measure: Proportion of subjects achieving an overall sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline.
timeFrame: 1 year
measure: Proportion of subjects who have 90% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI90).
timeFrame: 1 year
Other outcomes:
Locations:
city: Peking
country: China
facility: Peking University People's Hospital
state: Beijing
Study officials:
affiliation: Peking University People's Hospital
name: jianzhong Zhang
role: PRINCIPAL_INVESTIGATOR
References: